Thu.Oct 17, 2024

article thumbnail

3rd time's the charm: AbbVie scores FDA nod for continuous Parkinson's disease therapy Vyalev

Fierce Pharma

AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system innovation in the space as drugmakers sought to avoid the common pitfall | The 24-hour Parkinson's disease therapy crossed the FDA finish line after an initial manufacturing-related rejection last year and another snub in June.

FDA 317
article thumbnail

Innovating allergy drug delivery with a needle-free alternative

European Pharmaceutical Review

In August 2024, the European Commission approved EURneffy (adrenaline nasal spray) in the EU as the first needle-free emergency option to treat anaphylaxis. This decision was granted a couple of weeks following approval by the US and Drug Administration (FDA). What are the main advantages of EURneffy over similar treatments? EURneffy was determined by the European Medicines Agency (EMA) to be interchangeable with injection products given it provides the comparable exposures to epinephrine (adren

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novartis falls short in legal effort to undo FDA approval of MSN's Entresto generic

Fierce Pharma

As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss pharma’s top-selling drug Entresto. | In a court decision filed in Washington, D.C., U.S. District Judge Dabney Friedrich rejected Novartis’ position that the FDA’s approval of MSN’s Entresto generic was unlawful. In issuing the decision, the judge upheld the green light that MSN won in July.

FDA 316
article thumbnail

Medicaid’s Health Equity Problem Starts and Ends with Health-Related Social Needs (HRSNs). Why Are They Being Overlooked?

MedCity News

While federal healthcare programs focus their attention on ensuring healthcare resources exist for communities in need, HRSNs become critical drivers of whether individuals can actually access and benefit from these resources. The post Medicaid’s Health Equity Problem Starts and Ends with Health-Related Social Needs (HRSNs). Why Are They Being Overlooked?

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

NIH study shows Bavarian Nordic's mpox shot elicits immune response in teens

Fierce Pharma

With the clade 1 outbreak of mpox (formerly monkeypox) raging through the Congo and other countries in Central Africa, younger people have become markedly

277
277
article thumbnail

Should CVS Health Break Up?

MedCity News

CVS Health is reportedly exploring a breakup. But some experts aren’t sure if this is a good idea. The post Should CVS Health Break Up? appeared first on MedCity News.

Retail 120

More Trending

article thumbnail

First human skin atlas points way to healing without scars

pharmaphorum

The first human skin atlas is helping researchers to understand how skin forms, the mechanisms behind disorders, and could usher in scarless healing

115
115
article thumbnail

Viatris makes good on CEO's dealmaking promise with $25M licensing pact for Lexicon's heart med Inpefa

Fierce Pharma

After Viatris’ CEO earlier this year promised to be “opportunistic” about future business development moves, the company is making good on that pledge with a new licensing pact to bolster its cardi | Viatris is ponying up $25 million upfront to obtain the rights to sell Lexicon Pharmaceuticals’ SGLT1/SGLT2 heart med sotagliflozin, known commercially as Inpefa, in all global markets beyond the U.S. and Europe.

article thumbnail

Sage cuts a third of its workforce after R&D setbacks

pharmaphorum

Sage has launched another round of layoffs as it deals with the fallout of dropping a key pipeline drug for Alzheimer's and Parkinson's

114
114
article thumbnail

Direct to Patient Healthcare

Healthcare Success

Struggling with burnout while maintaining high-quality healthcare services that patients love? Tune in to our latest podcast as Lee Aase, founder of HELPCare, LLC, shares how he transitioned from his pioneering social media work at Mayo Clinic to lead an innovative membership-based direct-to-patient healthcare business. This podcast is a must-listen for healthcare leaders and primary care practitioners seeking innovative ways to enhance patient access, optimize care delivery, and address challen

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Gut Health Can Be a Workplace Equity Issue. Here’s How HR Leaders Can Prevent That

MedCity News

Now is a great time for employers to consider the impact GI health has on workplace equity and take steps to ensure they’re doing what they can to create an equitable workplace The post Gut Health Can Be a Workplace Equity Issue. Here’s How HR Leaders Can Prevent That appeared first on MedCity News.

113
113
article thumbnail

NICE backs first targeted therapy for ALK+ lung cancer

pharmaphorum

NICE backs NHS use of Roche's Alecensa as first adjuvant therapy for ALK+ NSCLC, and peri-operative use of MSD's Keytruda for all-comer NSCLC patients

Patients 105
article thumbnail

Glaukos eyes FDA approval for ocular therapy after Phase III win

Pharmaceutical Technology

The company’s keratoconus medication, Epioxa, was effective in a Phase III trial, with plans to file for submission with the US Food and Drug Administration (FDA).

article thumbnail

Wave sees RNA editing validation in early trial results

PharmaVoice

The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Vivan renews five-year lease at UK biotech hub White City Place

PharmaTimes

The London hub is home to life sciences companies including Novartis, Engitix and invoX Pharma

Pharma 94
article thumbnail

Australia joins EU in turning down Alzheimer's drug Leqembi

pharmaphorum

Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy Leqembi, saying its efficacy does not outweigh its risks.

89
article thumbnail

New ÂŁ4.5m initiative launched to address UK medicines manufacturing skills shortage

PharmaTimes

The two-year programme will use virtual reality technology to teach essential skills

article thumbnail

Sanofi Puts Up €300M in New Targeted Radiation Cancer Therapy Pact With Orano

MedCity News

Sanofi’s equity investment in the new Orano Med entity comes a month after the pharmaceutical giant struck a €100 million deal to license a clinical-stage radiopharmaceutical developed for neuroendocrine tumors. Orano Med develops targeted cancer therapies based on lead-212, an alpha-emitting isotope. The post Sanofi Puts Up €300M in New Targeted Radiation Cancer Therapy Pact With Orano appeared first on MedCity News.

Leads 80
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Health Canada approves Acadia’s DAYBUE for Rett syndrome

Pharmaceutical Technology

Acadia Pharmaceuticals has received marketing authorisation from Health Canada for DAYBUE (trofinetide) to treat Rett syndrome.

article thumbnail

Understanding AI-assisted patent drafting: What attorneys need to know

Clarivate

Artificial intelligence (AI) already enhances a range of legal processes. From contract and due diligence reviews to e-discovery and legal research, early adopters of AI have seen undeniable benefits in speed, accuracy and efficiency. Today, AI promises many of the same benefits in the context of patent preparation and prosecution. However, between the decision to invest in AI-assisted patent drafting software and achieving a positive return on investment, a lot of hype and mischaracterization c

article thumbnail

Humanizing Pharmacy: Shifting From Volume to Value for Improved Care and Reduced Pharmacist Burnout

Pharmacy Times

Retail pharmacies benefit from the shift from a volume-centric model to a value-centric approach that focuses on enhancing patient care, reducing pharmacist burnout, and leveraging technology to improve efficiency and expand the scope of pharmacy services.

Retail 67
article thumbnail

Increasing your likelihood of success in dealmaking discussions

Clarivate

In-licensing and acquisitions are fast tracks for pharmaceutical companies to access groundbreaking technologies and assets that will drive the next generation of transformative patient treatments. Dealmaking is not a trivial process. Audience members during the recent Clarivate webinar Emerging Deal Trends in Biotech and Pharma identified three of the biggest challenges they face when securing deals.

Pharma 59
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Sage lays off 55% of R&D workforce and refocuses pipeline

Pharmaceutical Technology

Strategic restructuring will support the ongoing launch of the oral postpartum depression drug, Zurzuvae, and extend Sage’s cash runway.

59
article thumbnail

Unmasking Health Care Fraud: RICO Is Increasingly Being Used in the Pharmaceutical Industry

Pharmacy Times

RICO is being leveraged in the pharmaceutical industry with significant implications for insurers and public trust.

article thumbnail

OIG’s Call for Increased Oversight of Remote Patient Monitoring Misses the Mark

Nixon Gwilt Law

In late September 2024, the Office of Inspector General (OIG) issued a report recommending additional oversight of Remote Patient Monitoring (RPM) in Medicare. The report highlights key areas where OIG believes more safeguards and transparency are necessary to ensure RPM services are being properly utilized and billed. Below, we summarize the OIG’s main findings and explain why we believe certain recommendations may be unnecessary and could actually reduce patient access to remote monitoring ser

article thumbnail

op Pharma Marketing Trends Shaping the Future of Healthcare in 2025

Pharma Marketing Network

As we approach 2025, the pharmaceutical industry is witnessing a seismic shift in marketing strategies, driven by technological advancements and evolving consumer expectations. These trends are not only transforming how pharmaceutical companies engage with healthcare professionals and patients but also shaping the future of healthcare delivery. This article explores the top pharma marketing trends that are set to redefine the landscape in the coming years.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Access Insights 2024: Financial Headwinds and Tailwinds to Commercialization

Pharmaceutical Commerce

Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses the key takeaways of this year's keynote speech.

article thumbnail

The Power of Healthcare Branding: Strategies for Pharma Marketing Success in 2025

Pharma Marketing Network

In an increasingly competitive pharmaceutical landscape, the significance of healthcare branding has never been more pronounced. As we approach 2025, the ability of pharmaceutical companies to effectively craft and communicate their brand identity will play a pivotal role in determining their market success. This article delves into the essence of healthcare branding and explores strategic approaches for pharma marketing, emphasizing the importance of digital platforms and the measurement of bra

article thumbnail

OIG’s Call for Increased Oversight of Remote Patient Monitoring Misses the Mark

Nixon Gwilt Law

In late September 2024, the Office of Inspector General (OIG) issued a report recommending additional oversight of Remote Patient Monitoring (RPM) in Medicare. The report highlights key areas where OIG believes more safeguards and transparency are necessary to ensure RPM services are being properly utilized and billed. Below, we summarize the OIG’s main findings and explain why we believe certain recommendations may be unnecessary and could actually reduce patient access to remote monitoring ser

article thumbnail

Sanofi, Orano Strike Deal to Develop Radioligand Medicines for Rare Cancers

PharmExec

Partnership is expected to develop radioligand therapies based on lead-212 alpha-emitting isotopes, which offer the opportunity to destroy cancer cells with minimal damage to healthy tissue.

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A